ZAZA ANTONIO
- U03, Piano: 3, Stanza: 3011
Pubblicazioni
Arici, M., Hsu, S., Ferrandi, M., Barassi, P., Ronchi, C., Torre, E., et al. (2024). Selective SERCA2a activator as a candidate for chronic heart failure therapy. JOURNAL OF TRANSLATIONAL MEDICINE, 22(1) [10.1186/s12967-024-04874-9]. Dettaglio
Maniezzi, C., Eskandr, M., Florindi, C., Ferrandi, M., Barassi, P., Sacco, E., et al. (2024). Early consequences of the phospholamban mutation PLN-R14del+/− in a transgenic mouse model. ACTA PHYSIOLOGICA, 240(3 (March 2024)) [10.1111/apha.14082]. Dettaglio
Maniezzi, C., Eskandr, M., Florindi, C., Ferrandi, M., Barassi, P., Sacco, E., et al. (2023). Early consequences of the phospholamban mutation PLN-R14del+/- in a transgenic mouse model [Altro] [10.1101/2023.04.05.535536]. Dettaglio
Giannetti, F., Barbieri, M., Shiti, A., Casini, S., Sager, P., Das, S., et al. (2023). Gene- and variant-specific efficacy of serum/glucocorticoid-regulated kinase 1 inhibition in long QT syndrome types 1 and 2. EUROPACE, 25(5 (May 2023)) [10.1093/europace/euad094]. Dettaglio
Arici, M., Ferrandi, M., Barassi, P., Hsu, S., Torre, E., Luraghi, A., et al. (2023). Istaroxime Metabolite PST3093 Selectively Stimulates SERCA2a and Reverses Disease-Induced Changes in Cardiac Function. THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 384(1), 231-244 [10.1124/jpet.122.001335]. Dettaglio